Global esophageal cancer
therapeutics market is expected to witness significant
growth with an increasing awareness regarding cancer treatment and technological
advancements. Also, high demand for safe and effective medications and rising prevalence
of cancer are driving the growth of the global market. The regulatory bodies such
as USFDA, EMA are supporting the growth of the global market by providing
funding, designations and grants for speeding up the drug development process.
Esophageal cancer involves
formation of malignant cells in the tissues of the esophagus. Esophagus is a
muscular tube that enable food and liquids to move from the throat to the
stomach. The main types of esophageal cancer are adenocarcinoma and squamous
cell carcinoma. Adenocarcinoma forms in cells that produce and release mucus
and other fluids. Squamous cell carcinoma forms in flat cells lining the
esophagus. Esophageal squamous cell carcinoma includes heavy alcohol
consumption and smoking as major risk factors, with gastroesophageal reflux
disease and Barrett esophagus further contributing as the risk factors of
esophageal adenocarcinoma. Esophageal cancer has no early signs or symptoms; therefore,
an advanced stage diagnosis is difficult.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/esophageal-cancer-therapeutics-market/report-sample
The marketed
drugs for esophageal cancer treatment includes Ramucirumab (Cyramza), Docetaxel
(Docefrez), and Trastuzumab (Herceptin) for adenocarcinoma. Also, XELIRI and
FU-LV are combination drugs given along with the chemotherapy that contributes
in the global esophageal cancer therapeutics market.
Genentech, Inc. markets
Trastuzumab (Herceptin) in combination
with cisplatin and a fluoropyrimidine (either capecitabine or 5-fluorouracil),
for the treatment of patients with HER2-overexpressing metastatic gastric or
gastroesophageal (GE) junction adenocarcinoma who were not treated for
metastatic disease prior.
Certain
chemotherapy medications such as Doxorubicin, Bleomycin, Vinblastine,
Dacarbazine, Chlorambucil, Procarbazine Prednisolone, Mustine, Vincristine,
Etoposide, Cyclophosphamide, Gemcitabine, Cisplatin and Cytarabine are well
established as a conventional method. Immunotherapy, combination therapy,
monoclonal antibodies and steroids have also been showing good results for the
treatment of esophageal cancer.
Explore Report at: https://www.psmarketresearch.com/market-analysis/esophageal-cancer-therapeutics-market
